Incyte (INCY) Share-based Compensation (2010 - 2026)
Incyte (INCY) posted Share-based Compensation of $7.0 million for Q1 2026, up 105.68% on a QoQ basis from -$122.4 million in Q3 2025, and down 88.59% year-over-year from $61.0 million in Q1 2025.
Incyte (INCY) Share-based Compensation (2010 - 2026) Analysis & Trends
Incyte's Share-based Compensation history runs 17 years deep, the most recent figure standing at $7.0 million for Q1 2026.
- Quarterly Share-based Compensation fell 88.59% year-over-year to $7.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$50.9 million (down 115.85% YoY) and the FY2025 annual result came in at $3.2 million, down 98.81% from the prior year.
- Share-based Compensation was $7.0 million for Q1 2026 at Incyte, up from -$122.4 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $263.6 million in Q4 2024 and bottomed at -$122.4 million in Q3 2025.
- A 5-year average of $36.0 million and a median of $23.3 million in 2023 frame the typical range for Share-based Compensation.
- Peak annual rise in Share-based Compensation reached 2370.11% in 2023, while the deepest fall reached 203.45% in 2023.
- Incyte's Share-based Compensation stood at $184.8 million in 2022, then tumbled by 87.4% to $23.3 million in 2023, then jumped by 1032.64% to $263.6 million in 2024, then tumbled by 146.44% to -$122.4 million in 2025, then soared by 105.68% to $7.0 million in 2026.
- Business Quant data shows INCY's Share-based Compensation at $7.0 million in Q1 2026, -$122.4 million in Q3 2025, and $64.6 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Incyte | 23.33 Bn | 19.32 Bn | 1.17 Bn | 6.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.96 Mn |
| Mar 31, 2026 | 6.96 Mn |
| Sep 30, 2025 | -122.43 Mn |
| Sep 30, 2025 | -122.43 Mn |
| Jun 30, 2025 | 64.61 Mn |
| Jun 30, 2025 | 64.61 Mn |
| Mar 31, 2025 | 60.98 Mn |
| Mar 31, 2025 | 60.98 Mn |
| Dec 31, 2024 | 263.62 Mn |
| Dec 31, 2024 | 263.62 Mn |
| Sep 30, 2024 | -113.98 Mn |
| Sep 30, 2024 | -113.98 Mn |
| Jun 30, 2024 | 110.24 Mn |
| Jun 30, 2024 | 110.24 Mn |
| Mar 31, 2024 | 6.17 Mn |
| Mar 31, 2024 | 6.17 Mn |
| Dec 31, 2023 | 23.28 Mn |
| Dec 31, 2023 | 23.28 Mn |
| Jun 30, 2023 | -48.10 Mn |
| Jun 30, 2023 | -48.10 Mn |